Dimethyl Fumarate Treatment for Intracranial Unruptured Aneurysms.
Key facts
- Phase
- Phase 4
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT05959759
- Record updated
- 20 August 2026
- Original description
This study was designed to identify whether there is a measurable reduction in inflammation in walls of intracranial aneurysms with oral dimethyl fumarate.Read full original descriptionShow less
Dimethyl Fumarate Treatment for Intracranial Unruptured Aneurysms: a Double Blind Randomized Controlled Trail
This study was designed to identify whether there is a measurable reduction in inflammation in walls of intracranial aneurysms with oral dimethyl fumarate.
Inclusion: Male or female aged ≥18 years; Unruptured IA of ≥3mm identified on imaging (CT, MRI or digital subtraction angiography); Aneurysm wall enhancement identified by HR-VWI before treatment; Ability to understand the objective of the trial with provision of written informed consent.
Exclusion: Current treatment with drugs that might have an anti-inflammatory effect (aspirin, statins, immunosuppressive drugs, angiotensin converting enzyme, etc.); Poor compliance with treatment or follow--up (patients who refuse to take medication as prescribed, patients who decline imaging follow--up or blood test, etc); MRI contraindications (metallic implant, contrast allergy, claustrophobia, etc); Malignant diseases (liver disease, kidney disease, congestive heart failure, malignant tumours, etc.); Planned treatment of the aneurysm within 6 months; Severely impaired liver or renal function; Retreatment of recurrent aneurysm; Pregnant or lactating women.